HRAS and cancer: Of the oncogenic mutations in the RAS family, the KRAS locus is the most often affected with a relatively higher prevalence in about 30% of cancerous tumors, while the HRAS and NRAS locus mutations are present in a modest 8% and 3%, respectively (Fernandez-Medarde and Santos, 2011).